Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing is tough enough; add gene-therapy jargon and Abeona Therapeutics鈥� disclosures can feel impenetrable. Whether you are tracking cash runway for pivotal trials or gauging FDA feedback on its pz-cel program, each 8-K and 10-K is packed with scientific nuance investors can鈥檛 afford to miss.
Stock Titan turns that complexity into clarity. Our AI-powered summaries cut through the 200-page annual report so you immediately see clinical milestones, manufacturing expenditures, and risk factors鈥�Abeona Therapeutics annual report 10-K simplified. Need fresh numbers? The Abeona Therapeutics quarterly earnings report 10-Q filing posts here seconds after EDGAR releases, complete with trend charts and a plain-English breakdown. Material news arrives first via Abeona Therapeutics 8-K material events explained, while understanding Abeona Therapeutics SEC documents with AI means no more deciphering footnotes alone.
Curious about management鈥檚 own trades before key read-outs? Our real-time alerts surface every Abeona Therapeutics insider trading Form 4 transactions, plus historical context for Abeona Therapeutics executive stock transactions Form 4. You鈥檒l also find the Abeona Therapeutics proxy statement executive compensation with easy-to-scan pay tables and governance scores. Below is everything available in one place:
- 10-K and 10-Q filings with AI commentary鈥�Abeona Therapeutics earnings report filing analysis
- 8-K event notices covering trial data, financings and CMC updates
- Abeona Therapeutics Form 4 insider transactions real-time feed
- DEF 14A proxy statements for compensation and voting matters
All documents refresh automatically, so the moment Abeona files, you鈥檙e already informed.
Insider transaction summary
On 18 Jul 2025, Maplebear Inc. (CART) Chief Product Officer Daniel Danker filed a Form 4 reporting the sale of 10,037 common shares under a Rule 10b5-1 trading plan adopted 28 Feb 2025.
- 9,745 shares sold at a weighted-average price of $48.7971.
- 292 shares sold at a weighted-average price of $49.5382.
- Estimated gross proceeds 鈮� $0.49 million.
- Direct ownership after the transactions: 470,190 shares (down from 480,227).
No derivative activity or other material corporate events were disclosed. The filing appears routine and primarily reflects personal portfolio management by the executive.
Federal Agricultural Mortgage Corporation (Farmer Mac) filed a Form 8-K disclosing a leadership change in its finance organization. On 8 July 2025, Executive Vice President & Chief Financial Officer (CFO) Aparna Ramesh notified the company she will resign effective 31 July 2025 to pursue another opportunity. The company states the departure is not related to any disagreement over accounting, reporting, internal controls or operations.
The Board has engaged an executive search firm to conduct a nationwide search for a permanent successor. In the interim, beginning 1 August 2025, Gregory N. Ramsey鈥攃urrently Vice President & Chief Accounting Officer鈥攚ill assume the role of principal financial officer. Ramsey, 61, has served as Farmer Mac鈥檚 principal accounting officer since 2013 and previously filled the interim CFO role from July 2019 to January 2020. No new compensatory arrangements were announced, and the filing reports no related-party transactions.
While a senior-level departure can introduce short-term uncertainty, the appointment of an experienced internal executive and the absence of accounting disputes help contain governance risk. There is no immediate financial impact disclosed, and all other terms of the company鈥檚 securities remain unchanged.
Federal Agricultural Mortgage Corporation (Farmer Mac) filed a Form 8-K disclosing a leadership change in its finance organization. On 8 July 2025, Executive Vice President & Chief Financial Officer (CFO) Aparna Ramesh notified the company she will resign effective 31 July 2025 to pursue another opportunity. The company states the departure is not related to any disagreement over accounting, reporting, internal controls or operations.
The Board has engaged an executive search firm to conduct a nationwide search for a permanent successor. In the interim, beginning 1 August 2025, Gregory N. Ramsey鈥攃urrently Vice President & Chief Accounting Officer鈥攚ill assume the role of principal financial officer. Ramsey, 61, has served as Farmer Mac鈥檚 principal accounting officer since 2013 and previously filled the interim CFO role from July 2019 to January 2020. No new compensatory arrangements were announced, and the filing reports no related-party transactions.
While a senior-level departure can introduce short-term uncertainty, the appointment of an experienced internal executive and the absence of accounting disputes help contain governance risk. There is no immediate financial impact disclosed, and all other terms of the company鈥檚 securities remain unchanged.
Federal Agricultural Mortgage Corporation (Farmer Mac) filed a Form 8-K disclosing a leadership change in its finance organization. On 8 July 2025, Executive Vice President & Chief Financial Officer (CFO) Aparna Ramesh notified the company she will resign effective 31 July 2025 to pursue another opportunity. The company states the departure is not related to any disagreement over accounting, reporting, internal controls or operations.
The Board has engaged an executive search firm to conduct a nationwide search for a permanent successor. In the interim, beginning 1 August 2025, Gregory N. Ramsey鈥攃urrently Vice President & Chief Accounting Officer鈥攚ill assume the role of principal financial officer. Ramsey, 61, has served as Farmer Mac鈥檚 principal accounting officer since 2013 and previously filled the interim CFO role from July 2019 to January 2020. No new compensatory arrangements were announced, and the filing reports no related-party transactions.
While a senior-level departure can introduce short-term uncertainty, the appointment of an experienced internal executive and the absence of accounting disputes help contain governance risk. There is no immediate financial impact disclosed, and all other terms of the company鈥檚 securities remain unchanged.
Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.
Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company鈥檚 outstanding stock, indicating minimal dilution risk.
The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:
- 09 Jul 2025 鈥� 200 shares 鈥� $602.00
- 22 May 2025 鈥� 1,179 shares 鈥� $2,458.33
- 21 May 2025 鈥� 600 shares 鈥� $1,262.52
- 20 May 2025 鈥� 800 shares 鈥� $1,736.72
- 19 May 2025 鈥� 1,000 shares 鈥� $2,226.60
- 16 May 2025 鈥� 1,421 shares 鈥� $3,326.13
Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.
Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.
Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company鈥檚 outstanding stock, indicating minimal dilution risk.
The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:
- 09 Jul 2025 鈥� 200 shares 鈥� $602.00
- 22 May 2025 鈥� 1,179 shares 鈥� $2,458.33
- 21 May 2025 鈥� 600 shares 鈥� $1,262.52
- 20 May 2025 鈥� 800 shares 鈥� $1,736.72
- 19 May 2025 鈥� 1,000 shares 鈥� $2,226.60
- 16 May 2025 鈥� 1,421 shares 鈥� $3,326.13
Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.
Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.
Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company鈥檚 outstanding stock, indicating minimal dilution risk.
The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:
- 09 Jul 2025 鈥� 200 shares 鈥� $602.00
- 22 May 2025 鈥� 1,179 shares 鈥� $2,458.33
- 21 May 2025 鈥� 600 shares 鈥� $1,262.52
- 20 May 2025 鈥� 800 shares 鈥� $1,736.72
- 19 May 2025 鈥� 1,000 shares 鈥� $2,226.60
- 16 May 2025 鈥� 1,421 shares 鈥� $3,326.13
Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.
Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.
Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company鈥檚 outstanding stock, indicating minimal dilution risk.
The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:
- 09 Jul 2025 鈥� 200 shares 鈥� $602.00
- 22 May 2025 鈥� 1,179 shares 鈥� $2,458.33
- 21 May 2025 鈥� 600 shares 鈥� $1,262.52
- 20 May 2025 鈥� 800 shares 鈥� $1,736.72
- 19 May 2025 鈥� 1,000 shares 鈥� $2,226.60
- 16 May 2025 鈥� 1,421 shares 鈥� $3,326.13
Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.
FAQ
What is the current stock price of Abeona Therapeut (ABEO)?
What is the market cap of Abeona Therapeut (ABEO)?
What is the primary focus of Abeona Therapeutics Inc?
What type of technologies does Abeona utilize in its research?
How does Abeona develop its therapies?
What is the role of regulatory compliance in Abeona's operations?
How does Abeona鈥檚 pipeline reflect its commitment to innovation?
What significance do FDA inspections and regulatory milestones have for Abeona?
How does Abeona differentiate itself from competitors?
What are the key challenges faced by clinical-stage biotech companies like Abeona?
